In the News

Aetion Launches Research Collaboration with FDA to Advance Understanding of COVID-19

Aetion has signed a research collaboration agreement with the U.S. Food and Drug Administration to use real-world data to advance the understanding of and response to coronavirus disease (COVID-19). The research will support the FDA’s objectives to explore the natural history of the disease, as well as treatment and...

U.S. Sees Dramatic Drop in Routine Testing Amid Pandemic

A new report from Komodo Health shows that diagnostic testing for cancer and other conditions has declined across the U.S. since mid-March following regional lockdowns for the COVID-19 pandemic. Komodo Health analyzed billing records of 320 million patients from March 19 through April 20 and found that cervical...

GRAIL to Participate in BofA Securities 2020 Health Care Conference

GRAIL has announced that two of its executives will be speaking at the BofA Securities 2020 Health Care Conference. Hans Bishop, Chief Executive Officer; and Joshua Ofman, MD, MSHS, Chief Medical Officer and External Affairs, will provide an overview of the company at the virtual conference, which will take place...

Vivante Health Joins Accolade Trusted Supplier Program

Vivante Health, a provider of digital medicine tools for digestive health and disease, has joined the Accolade Partner Ecosystem as part of the company’s Trusted Supplier Program. GIThrive is Vivante’s digital gut health platform. Using proprietary algorithms and data from each user’s symptom and food log, GIThrive...

COVID-19: The Critical Role of Real-World Evidence Made Real

In response to the COVID-19 pandemic, the HLTH Matters Blog Series will be interviewing experts from across the health ecosystem to bring timely facts and updates to the HLTH community. A post written by Aetion CEO Carolyn Magill details the role of real-world evidence in the fight against coronavirus. “I’m certain...

Cancer screenings plunge more than 90% due to COVID-19

Electronic health record software provider Epic released data indicating that appointments for cervix, colon, and breast cancer screenings have dropped between 86 percent and 94 percent compared to average volumes in the three years before the confirmation of the first COVID-19 case in the U.S. At the end of April,...

Press Releases